NVS vs VNDA
NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience. VNDA: Vanda Pharmaceuticals is a specialty biopharmaceutical company commercializing psychiatric and neurological therapies while advancing a pipeline focused on pharmacogenetic-driven precision medicine.
Side-by-side fundamentals
| Metric | NVS | VNDA | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $153.93 | $4.01 | |
| Market cap | $286.6B | $242M | |
| Net margin FY2025, SEC XBRL | n/a | -102.0% | |
| Operating margin FY2025, SEC XBRL | n/a | -70.0% | |
| ROE FY2025, SEC XBRL | +30.0% | -67.4% | NVS higher |
| ROA FY2025, SEC XBRL | +12.6% | -45.1% | NVS higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +8.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -5.3% | |
| Dividend yield as of 2026-09-03 | +3.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.22 | 0.64 | |
| 1-year return as of 2026-10-21 close | +17.2% | -24.2% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.